BOSTON–(BUSINESS WIRE)–Alloy Therapeutics, Inc. (“Alloy”), a biotechnology ecosystem company powering the future of drug discovery and development through AI-driven platforms and integrated services, today announced a $40 million Series E financing round, marking a significant step in the company’s evolution from antibody discovery pioneer to full-stack biotech infrastructure company. This latest round of financing values Alloy at $1 billion.
Read more here.